The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

(2013) M. Pratcorona et al.   BLOOD

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

(2013) E. Jourdan et al.   BLOOD

The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

(2012) F. Schneider et al.   BLOOD

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)

(2012) P. Paschka et al.   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816

(2011) Soo Young Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice

(2011) L. Zhao et al.   BLOOD

N-RasG12D induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene

(2011) F.-S. Chou et al.   BLOOD

Blood consult: acute myeloid leukemia and the t(8;21)(q22;22)

(2011) J. H. Park et al.   BLOOD

Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia

(2011) H. J. Nick et al.   BLOOD

Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

(2011) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

(2011) S Schnittger et al.   LEUKEMIA

Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia

(2011) Sang Hyuk Park et al.   LEUKEMIA RESEARCH

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

(2011) Y.-Y. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations

(2010) Y. Yang et al.   BLOOD

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

(2010) J. A. Pollard et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Myeloid Leukemia Development in c-Cbl RING Finger Mutant Mice Is Dependent on FLT3 Signaling

(2010) Chozhavendan Rathinam et al.   CANCER CELL

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions

(2010) C Haferlach et al.   LEUKEMIA

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes

(2009) C. Reindl et al.   CLINICAL CANCER RESEARCH

Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial

(2009) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease

(2008) A. J. Mead et al.   BLOOD

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia

(2008) Krzysztof Mrózek et al.   CURRENT OPINION IN ONCOLOGY

Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias

(2008) S. Abbas et al.   HAEMATOLOGICA

HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR

(2007) Richard F. Schlenk et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION